Fred Alger Management’s Astria Therapeutics ATXS Stock Holding History

Fred Alger Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-738	Closed	-$160K	–	526
2016 Q4	$160K	Sell	738 -625	-46%	-$153K	﹤0.01%	357
2016 Q3	$504K	Sell	1,363 -83	-6%	-$21.9K	﹤0.01%	354
2016 Q2	$321K	Sell	1,446 -467	-24%	-$141K	﹤0.01%	400
2016 Q1	$579K	Sell	1,913 -717	-27%	-$247K	﹤0.01%	409
2015 Q4	$1.25M	Buy	+2,630	New	+$1.26M	0.01%	366
2015 Q3	–	Sell	-333	Closed	-$244K	–	469
2015 Q2	$244K	Buy	+333	New	+$252K	﹤0.01%	493

Other funds holding ATXS

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Fred Alger Management's ATXS Position: Q1 2017 in Review

Fred Alger Management sold out of Astria Therapeutics (ATXS) in Q1 2017, closing a stake of 738 shares — an estimated $160K sold.

Fred Alger Management first reported a position in ATXS in Q2 2015 and held it in 6 quarters. The position peaked at $1.25M in Q4 2015. 23 funds tracked by Wall St. Rank hold ATXS as of Q1 2017.

Fred Alger Management reported no remaining Astria Therapeutics position as of Q1 2017 after selling out during the quarter.
Fred Alger Management sold 738 Astria Therapeutics shares in Q1 2017, an estimated $160K.
Fred Alger Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 6 quarters.
Fred Alger Management's Astria Therapeutics position peaked at $1.25M in Q4 2015.
23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2017.

Based on Fred Alger Management's 13F filing for Q1 2017, filed 15 May 2017.